Post-marketing Surveillance (PMS) of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) -16/18 Vaccine, Cervarix™ When Administered to Healthy Females According to the Prescribing Information in Sri Lanka
Subjects who received one or two doses of Cervarix prior to the start of this PMS study can
also be enrolled in the study. These subjects would receive either 2 doses or 1 dose
respectively after being enrolled in the study.
Observational Model: Cohort, Time Perspective: Prospective
Occurrence of solicited local adverse events (AEs).
During the 7-day period (Days 0-6) following any dose of Cervarix and overall.
GSK Clinical Trials
Sri Lanka: Cosmetics, Devices and Drug Regulatory Authority